Dermata Therapeutics
DRMA
Dermata Therapeutics (DRMA) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$1.66
- EPS estimate
- −$2.90
- EPS surprise
- +42.76%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 13, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 13, 2025 | −$2.90 | −$1.66 | +42.76% | $0.00 | SEC |
| Q1 2025 | May 14, 2025 | −$4.50 | −$4.50 | +0.00% | $0.00 | SEC |
| Q4 2024 | Mar 17, 2025 | −$15.00 | −$13.40 | +10.67% | $0.00 | SEC |
| Q3 2024 | Nov 13, 2024 | −$26.40 | −$20.40 | +22.73% | $0.00 | SEC |
| Q2 2024 | Aug 7, 2024 | −$37.90 | −$41.80 | −10.29% | $0.00 | SEC |
| Q1 2024 | May 15, 2024 | −$54.00 | −$4.70 | +91.30% | $0.00 | SEC |
| Q4 2023 | Mar 21, 2024 | −$117.00 | −$67.50 | +42.31% | $0.00 | SEC |
| Q3 2023 | Nov 9, 2023 | −$94.50 | −$81.00 | +14.29% | $0.00 | SEC |
| Q2 2023 | Aug 10, 2023 | −$138.00 | −$94.50 | +31.52% | $0.00 | SEC |
| Q1 2023 | May 11, 2023 | −$397.50 | −$340.50 | +14.34% | $0.00 | SEC |
| Q4 2022 | Feb 21, 2023 | −$480.00 | −$336.00 | +30.00% | $0.00 | SEC |
| Q3 2022 | Nov 10, 2022 | −$528.00 | −$480.00 | +9.09% | $0.00 | — |
| Q2 2022 | Aug 15, 2022 | −$768.00 | −$576.00 | +25.00% | $0.00 | — |
| Q1 2022 | May 16, 2022 | −$960.00 | −$792.00 | +17.50% | $0.00 | — |
| Q4 2021 | Mar 28, 2022 | −$1,008.00 | −$744.00 | +26.19% | $0.00 | — |
| Q2 2021 | Sep 27, 2021 | −$1,680.00 | −$1,680.00 | +0.00% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did Dermata Therapeutics (DRMA) last report earnings?
Dermata Therapeutics last reported on Aug 13, 2025, covering fiscal Q2 2025.
Did DRMA beat earnings estimates?
Yes. Dermata Therapeutics reported EPS of −$1.66 for Q2 2025 against a −$2.90 estimate — a 42.76% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.